the prevalence of cyp1a2*1c polymorphism in different ethnic of iranian population

Abstract; Background: Human CYP1A2 is one of the major CYPs in human liver and metabolizes a variety of clinically important drugs and caffeine (e.g., clozapine, tacrine, tizanidine, and theophylline) and caffeine. Its activity can be influenced by factors such as sex, age, and smoking. The single nucleotide polymorphism (SNP) rs762551A.C, which has also been studied for its modifying effect on cardiovascular disease, has been reported to alter enzyme activity. The allele was located on 15q24.1 locus. CYP1A2*1C polymorphism is decreased the effect of drugs. We investigated the prevalence of the CYP1A2*1C in an Iranian population of different ethnicities, including Azari , Lure , Fars , Kurd , and Caspian (mazani /Gilaki ) , in comparison to the frequency of the CYP1A2*1C in the other population.Material and method: In this study we were analyzed 300 blood samples of healthy individuals in an Iranian population. The present study was conducted to explore the allelic and genotypic frequencies of CYP1A2 gene polymorphisms, CYP1A2*1C (−3860 G> A) among 300 Iranian volunteers. The CYP1A2 polymorphisms (CYP1A2*1C) were genotyped by the PCR-RFLP (Restriction Fragment Length Polymorphism) method.Result: The G/C, G/A and A/A allelic frequencies of CYP1A2*1C were 9%, 79%, and 12% respectively. Additionally, the frequency of the homozygote(G/C) variant of CYP1A2*1C was high in the lure , Turk , Fars and low in the Kurd , Caspian ethnicities conclusion :these result suggest that the predication of the CYP1A2*1C allele is required in drug research and routine treatment ,where the information would be helpful for clinical optimize therapy or identify persons at risk of adverse drug reaction before clinical trials. In addition the ethnicities of Iran that have the polymorphism are the lure ,Turk ,Caspian, Fars and Kurds.Key word ; pholymorphism , pharmacogenetic ,ethinic ,CYP1A2*1C , Iran.

کلیدواژه ها:

pharmacogenetic ، polymorphism ، ethnic ، cyp1a2*1c ، iran Noninvasive ، Quantification